Sponsored by
The Phase 3 TRIDENT trial enrolled 981 newly diagnosed glioblastoma (GBM) patients to evaluate whether starting Tumor Treating Fields (TTFields) during radiation and temozolomide treatment could improve survival compared with the current approach of starting TTFields after chemoradiation is completed.
The trial did not meet its primary endpoint, with median overall survival of 17.7 months in the early-start group versus 17.5 months in the standard group. However, these results should not be interpreted as a negative study for TTFields itself. Both groups received TTFields; the question being tested was whether starting treatment earlier would provide additional benefit.
One encouraging finding was the long-term survival tail in both groups. Three-year survival rates were 22.5% in the early-start arm and 18.4% in the standard-start arm, which compares favorably with historical outcomes for newly diagnosed GBM.
While earlier initiation did not significantly improve overall survival in the overall study population, additional analyses may identify patient subgroups that derive greater benefit from earlier treatment. Novocure has not yet released detailed compliance (usage) data, which may provide additional insights when the full results are presented at the ASTRO 2026 Annual Meeting.